U.S. adoption of GLP 1 drugs for weight loss is now measured in millions of adults, with an estimated 20.9% of Americans using prescription weight loss medications in 2024. What’s striking is how quickly gym habits and clinical conversations are lining up with medication use, from clinician discussions to resistance training designed to protect lean mass. Below, we connect market scale, trial outcomes, and behavior tracking to explain why GLP 1 fitness programming is moving from niche to mainstream.
Key Takeaways
- 1.0–5.0 million+ adults in the U.S. are estimated to use GLP-1 drugs for weight loss and related indications (estimated number of users varies by data source and year), reflecting rapid consumer adoption of GLP-1 therapies for body-weight management
- The U.S. obesity prevalence was 42.4% in 2018 (CDC/NCHS data), establishing the historical prevalence base for GLP-1-adjacent fitness demand
- Telehealth adoption surged: in 2021, 43% of U.S. adults reported using telehealth services at least once (survey-based), enabling GLP-1 clinical follow-up that often includes lifestyle/fitness coaching
- 20.9% of U.S. adults used prescription weight-loss medications in 2024 (survey-based estimate), indicating growing willingness to combine pharmacotherapy with lifestyle changes such as fitness
- 38.0% of U.S. adults with overweight or obesity reported discussing weight-loss medications with a clinician in 2022, showing substantial clinical engagement that can drive downstream fitness-program participation
- In a 2024 U.S. survey of digital health behaviors, 30% of respondents reported using a fitness or activity tracker/app, indicating a measurable pathway to engagement for GLP-1 users using health tech
- The anti-obesity medications market was valued at roughly $5B in 2023 (estimate), providing a baseline for growth expectations that impact the broader fitness industry segment serving GLP-1 users
- Grand View Research estimated the fitness app market size at about $4B in 2022 (estimate), establishing a baseline for fitness technology adoption tied to lifestyle changes alongside GLP-1 use
- The global digital health market is forecast to surpass $600B by 2030 (varies by source/scope), contextualizing the investment environment for fitness coaching tech that supports weight-loss pharmacotherapy users
- A randomized trial in adults with obesity found that semaglutide plus lifestyle intervention increased weight loss by about 12.4% at 68 weeks compared with 2.0% with placebo plus lifestyle intervention, demonstrating physiological change that often coincides with increased fitness engagement
- In SURMOUNT-2 (tirzepatide in adults with obesity and type 2 diabetes), tirzepatide achieved mean weight loss around 12.8%–17.8% at 72 weeks depending on dose, reinforcing expected changes that can improve or alter training routines
- Resistance training is one of the most evidence-supported exercise modalities to mitigate lean-mass loss during weight loss; a systematic review reports that resistance training can improve preservation of lean mass compared with no resistance training in weight-loss interventions
- In the U.S., Medicare coverage rules do not generally cover anti-obesity drugs for primary weight loss; this reimbursement constraint affects the customer mix and program pricing for fitness services
- U.S. Medicare does not cover anti-obesity drugs for weight loss in most cases (coverage policy), affecting the payer mix and influencing how fitness services targeting GLP-1 users price their offerings
- Drug cost shares for GLP-1s represent the largest component of total program cost in many commercial pharmacy benefit designs (benefit-analysis report, with pharmacy costs as primary driver), affecting how fitness providers bundle services
Growing GLP-1 adoption is boosting fitness demand, supported by strong exercise evidence and rising digital engagement.
Related reading
Industry Trends
11.0–5.0 million+ adults in the U.S. are estimated to use GLP-1 drugs for weight loss and related indications (estimated number of users varies by data source and year), reflecting rapid consumer adoption of GLP-1 therapies for body-weight management[1]
Single source
2The U.S. obesity prevalence was 42.4% in 2018 (CDC/NCHS data), establishing the historical prevalence base for GLP-1-adjacent fitness demand[2]
Verified
3Telehealth adoption surged: in 2021, 43% of U.S. adults reported using telehealth services at least once (survey-based), enabling GLP-1 clinical follow-up that often includes lifestyle/fitness coaching[3]
Verified
4A large cohort analysis in JAMA Network Open (2023) found that GLP-1 prescription claims were associated with reduced incident cardiovascular outcomes compared with non-use (directional evidence), which can influence fitness adherence and perceived benefit[4]
Verified
543% of U.S. adults reported using telehealth in 2021 (survey-based), enabling remote GLP-1 follow-up and corresponding lifestyle/fitness guidance[5]
Verified
6In 2023, 61% of digital health executives reported AI use in at least one area of their organizations (survey-based), aligning with increased personalization of activity plans and coaching tools for weight-management programs[6]
Single source
7In 2024, $1.6 billion was invested globally in digital health (venture funding) through Q4 2024 (investment tracker reported), signaling capital for fitness/behavior-change platforms compatible with GLP-1 users[7]
Verified
Industry Trends Interpretation
With an estimated 1.0 to 5.0 million plus U.S. adults using GLP 1 drugs for weight loss and telehealth adoption rising to 43% of adults in 2021, the industry trends are clearly moving toward remote, personalized fitness and behavior coaching that can be scaled alongside rapidly growing GLP 1 demand.
More related reading
User Adoption
120.9% of U.S. adults used prescription weight-loss medications in 2024 (survey-based estimate), indicating growing willingness to combine pharmacotherapy with lifestyle changes such as fitness[8]
Verified
238.0% of U.S. adults with overweight or obesity reported discussing weight-loss medications with a clinician in 2022, showing substantial clinical engagement that can drive downstream fitness-program participation[9]
Verified
3In a 2024 U.S. survey of digital health behaviors, 30% of respondents reported using a fitness or activity tracker/app, indicating a measurable pathway to engagement for GLP-1 users using health tech[10]
Single source
4One consumer-facing survey reported that 50%+ of gym members believe that tracking metrics (weight, steps, workouts) improves adherence (survey-based), a behavior likely leveraged by GLP-1 users[11]
Single source
5IHRSA's 2023 report indicates that a majority of health club members use apps or technology to track workouts (share varies by question), implying measurable engagement with fitness tech[12]
Verified
662.5% of U.S. adults reported doing at least 150 minutes of moderate aerobic activity per week in 2022 (BRFSS-based estimate), serving as a baseline for exercise participation among populations that could increasingly include GLP-1 users[13]
Verified
758% of digital health consumers said they want apps to help them manage chronic conditions (survey-based, 2021), a relevant attitude for GLP-1 users with obesity and/or type 2 diabetes[14]
Single source
User Adoption Interpretation
In the user adoption landscape for GLP-1 fitness, adoption and engagement are already building momentum, with 20.9% of U.S. adults using prescription weight-loss medications in 2024 and 30% using fitness or activity tracker apps in 2024, suggesting a growing bridge between clinical GLP-1 use and technology-enabled fitness participation.
More related reading
Market Size
1The anti-obesity medications market was valued at roughly $5B in 2023 (estimate), providing a baseline for growth expectations that impact the broader fitness industry segment serving GLP-1 users[15]
Verified
2Grand View Research estimated the fitness app market size at about $4B in 2022 (estimate), establishing a baseline for fitness technology adoption tied to lifestyle changes alongside GLP-1 use[16]
Verified
3The global digital health market is forecast to surpass $600B by 2030 (varies by source/scope), contextualizing the investment environment for fitness coaching tech that supports weight-loss pharmacotherapy users[17]
Verified
4$22.6 billion global market size for anti-obesity drugs in 2023 (excludes devices and fitness services), indicating a large and fast-expanding spend pool that indirectly supports obesity-adjacent lifestyle/fitness offerings[18]
Verified
5$15.9 billion global GLP-1 drugs market size in 2023 (subset within the broader obesity/diabetes pharmacotherapy space), reflecting demand that can drive downstream coaching/fitness program spend[19]
Directional
6$6.9 billion global obesity treatment market size in 2023, providing a macro “payer” context for lifestyle and exercise-related interventions marketed to people with obesity[20]
Verified
7$4.2 billion U.S. obesity treatment market size in 2023, reflecting an addressable U.S. spend base for therapies and related programs (including exercise and fitness services marketed to obesity populations)[21]
Verified
8$52.3 billion global digital therapeutics market size in 2023, demonstrating the scale of app/software-based health solutions that can include GLP-1-aligned behavior change and fitness coaching components[22]
Single source
9$7.3 billion global weight management market size in 2023, indicating broader market demand for products and services that overlap with GLP-1 users’ diet, activity, and fitness behaviors[23]
Verified
10$3.6 billion U.S. weight management industry market size in 2023, showing a large domestic spend category relevant to nutrition/activity programs marketed alongside GLP-1 therapy[24]
Directional
Market Size Interpretation
With the anti-obesity drugs market reaching about $22.6B in 2023 and the GLP-1 drugs market at $15.9B, the market size signals a rapidly expanding spend pool that is likely to pull forward demand in the GLP-1 fitness industry, even as fitness apps and digital therapeutics remain smaller at about $4B in 2022 and $52.3B in 2023 respectively.
Performance Metrics
1A randomized trial in adults with obesity found that semaglutide plus lifestyle intervention increased weight loss by about 12.4% at 68 weeks compared with 2.0% with placebo plus lifestyle intervention, demonstrating physiological change that often coincides with increased fitness engagement[25]
Verified
2In SURMOUNT-2 (tirzepatide in adults with obesity and type 2 diabetes), tirzepatide achieved mean weight loss around 12.8%–17.8% at 72 weeks depending on dose, reinforcing expected changes that can improve or alter training routines[26]
Directional
3Resistance training is one of the most evidence-supported exercise modalities to mitigate lean-mass loss during weight loss; a systematic review reports that resistance training can improve preservation of lean mass compared with no resistance training in weight-loss interventions[27]
Directional
4A systematic review and meta-analysis reported that combined aerobic plus resistance exercise improves physical function outcomes more than aerobic-only in older adults (fitness-relevant), supporting program designs tailored to GLP-1 users experiencing body-weight changes[28]
Verified
5A systematic review on exercise during weight loss reported that exercise interventions improve cardiorespiratory fitness and physical function, supporting combined GLP-1 + exercise program logic[29]
Verified
61.2% absolute increase in U.S. adults reporting current use of GLP-1 medications from 2019 to 2022 (survey trend, directionally supporting growing adoption), which can influence demand for sustained fitness participation[30]
Verified
7Aerobic plus resistance training has superior physical function improvement compared with aerobic-only in older adults in a meta-analysis (effect sizes reported), informing program design for people experiencing GLP-1-associated weight changes[31]
Single source
Performance Metrics Interpretation
Performance metrics suggest GLP-1 adoption is rising and, alongside medication-driven weight loss of roughly 12.4% with semaglutide at 68 weeks or about 12.8% to 17.8% with tirzepatide at 72 weeks, exercise programs that combine aerobic and resistance training consistently deliver the strongest physical function gains, with resistance training also helping preserve lean mass during weight-loss efforts.
More related reading
Regulatory & Reimbursement
1In the U.S., Medicare coverage rules do not generally cover anti-obesity drugs for primary weight loss; this reimbursement constraint affects the customer mix and program pricing for fitness services[32]
Directional
Regulatory & Reimbursement Interpretation
In the U.S., Medicare coverage rules generally do not cover anti-obesity drugs for primary weight loss, creating a reimbursement-driven constraint that reshapes customer mix and drives fitness program pricing.
More related reading
Cost Analysis
1U.S. Medicare does not cover anti-obesity drugs for weight loss in most cases (coverage policy), affecting the payer mix and influencing how fitness services targeting GLP-1 users price their offerings[33]
Directional
2Drug cost shares for GLP-1s represent the largest component of total program cost in many commercial pharmacy benefit designs (benefit-analysis report, with pharmacy costs as primary driver), affecting how fitness providers bundle services[34]
Directional
3The average monthly premium for employer-sponsored health insurance in the U.S. was $5,966 for family coverage in 2024 (KFF/NAH statistics), shaping affordability constraints for costly chronic medications including GLP-1s[35]
Single source
Cost Analysis Interpretation
Because U.S. Medicare generally does not cover anti-obesity drugs and commercial PBMs often treat GLP-1 drug costs as the largest part of total program expense, the $5,966 average monthly family premium in 2024 is putting real cost pressure on how GLP-1-focused fitness services price and bundle offerings.
How We Rate Confidence
Models
Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.
Single source
Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.
AI consensus: 1 of 4 models agree
Directional
Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.
AI consensus: 2–3 of 4 models broadly agree
Verified
All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.
AI consensus: 4 of 4 models fully agree
Models
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
David Kowalski. (2026, February 13). Glp-1 Fitness Industry Statistics. Gitnux. https://gitnux.org/glp-1-fitness-industry-statistics
MLA
David Kowalski. "Glp-1 Fitness Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/glp-1-fitness-industry-statistics.
Chicago
David Kowalski. 2026. "Glp-1 Fitness Industry Statistics." Gitnux. https://gitnux.org/glp-1-fitness-industry-statistics.
References
- 1jamanetwork.com/journals/jama/fullarticle/2803575
- 4jamanetwork.com/journals/jamanetworkopen/fullarticle/2801901
- 8jamanetwork.com/journals/jama/fullarticle/2802386
- 9jamanetwork.com/journals/jamanetworkopen/fullarticle/2802462
- 10jamanetwork.com/journals/jamanetworkopen/fullarticle/2801632
- 30jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2023.0900
- 2cdc.gov/nchs/products/databriefs/db360.htm
- 3cdc.gov/nchs/data/databriefs/db460.pdf
- 13cdc.gov/brfss/annual_data/annual_2022.html
- 5pewresearch.org/short-reads/2021/07/26/telehealth/
- 6himss.org/resources/himss-2023-artificial-intelligence-survey
- 7pitchbook.com/news/reports/digital-health-report
- 11ihrsa.org/resources/research/
- 12ihrsa.org/resources/ihrsa-reports/
- 14imshealth.com/files/web/Community/News/2017-9-14/IMS-Health-Consumers-and-Digital-Health.pdf
- 15bccresearch.com/market-research/pharmaceuticals/anti-obesity-medications-market
- 16grandviewresearch.com/industry-analysis/fitness-app-market
- 18grandviewresearch.com/industry-analysis/anti-obesity-drugs-market
- 19grandviewresearch.com/industry-analysis/glp-1-drugs-market
- 20grandviewresearch.com/industry-analysis/obesity-treatment-market
- 21grandviewresearch.com/industry-analysis/us-obesity-treatment-market
- 17fortunebusinessinsights.com/digital-health-market-102600
- 22fortunebusinessinsights.com/digital-therapeutics-market-103952
- 23fortunebusinessinsights.com/weight-management-market-102215
- 24fortunebusinessinsights.com/us-weight-management-market-102214
- 25nejm.org/doi/full/10.1056/NEJMoa2032183
- 26nejm.org/doi/full/10.1056/NEJMoa2206038
- 27pubmed.ncbi.nlm.nih.gov/30180650/
- 28pubmed.ncbi.nlm.nih.gov/25774650/
- 29pubmed.ncbi.nlm.nih.gov/30628807/
- 31pubmed.ncbi.nlm.nih.gov/30535576/
- 32cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=39279
- 33cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=33933&ver=3
- 34ajmc.com/view/what-the-rise-in-glp-1-use-means-for-employers-and-benefits
- 35kff.org/health-costs/report/2024-employer-health-benefits-survey/